About Tirzepatide
Understanding the dual GIP/GLP-1 mechanism and how tirzepatide may support weight management when prescribed by a licensed provider.
What Is Tirzepatide?
Tirzepatide is a dual GIP/GLP-1 receptor agonist — a class of medication that targets two key hormonal pathways involved in appetite regulation and metabolic function. By activating both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, tirzepatide may influence how the body processes food and regulates hunger signals.
It is administered as a once-weekly subcutaneous injection, typically starting at a lower dose and gradually increasing based on the provider's clinical judgment and the patient's response.
Compounded tirzepatide is not FDA-approved. All treatment decisions are made by a licensed healthcare provider based on individual evaluation.
Dual Mechanism of Action
GIP Receptor Activation
May influence energy balance and fat metabolism through the glucose-dependent insulinotropic polypeptide pathway.
GLP-1 Receptor Activation
May help regulate appetite and gastric emptying through the glucagon-like peptide-1 pathway, which is also targeted by semaglutide.
Weekly Administration
Administered once weekly as a subcutaneous injection, with dosing determined and adjusted by your prescribing provider.
How the Care Process Works
Our telehealth platform connects you with licensed providers who evaluate whether tirzepatide may be appropriate for your situation.
Complete Your Profile
Share your health history, current medications, and weight management goals through our secure intake form.
Provider Evaluation
A licensed healthcare provider reviews your information and conducts a telehealth consultation to assess eligibility.
Prescription & Shipping
If prescribed, your medication is prepared by a licensed compounding pharmacy and shipped directly to you with discreet packaging.
Ongoing Support
Your provider monitors your progress, adjusts dosing when clinically appropriate, and provides continued guidance.
Who May Be Evaluated
Tirzepatide is not appropriate for everyone. Your eligibility is determined by a licensed provider based on your individual health profile.
You May Be Evaluated If
- You are an adult (18+) with a BMI of 30 or above
- Your BMI is 27+ with a weight-related health condition
- You are committed to concurrent lifestyle modifications
You May Not Qualify If
- You are pregnant, nursing, or planning pregnancy
- You have a history of MTC or MEN 2 syndrome
- You have a history of pancreatitis
This is a summary only. A licensed provider will conduct a comprehensive evaluation. See the full eligibility criteria for details.
Potential Benefits
When prescribed by a licensed provider, tirzepatide may offer the following benefits as part of a comprehensive weight management plan.
May Help Reduce Appetite
By activating GLP-1 receptors, tirzepatide may help regulate hunger signals, potentially reducing appetite and supporting portion control when combined with lifestyle changes.
Targets Two Pathways
Unlike single-receptor medications, tirzepatide activates both GIP and GLP-1 receptors, which may influence appetite regulation and metabolic function through complementary mechanisms.
May Support Weight Management
When combined with diet and exercise, tirzepatide may support clinically meaningful weight reduction in eligible patients. Individual results vary based on multiple factors.
Individual results may vary. Benefits are not guaranteed and depend on adherence to treatment, lifestyle modifications, and individual health factors. Compounded tirzepatide is not FDA-approved.
Important Considerations
Like all medications, tirzepatide carries potential risks and side effects. Your provider will discuss these with you during your evaluation.
Common Side Effects
The most commonly reported side effects are gastrointestinal in nature and may include:
These side effects are often mild to moderate and may diminish as the body adjusts. Your provider may use gradual dose escalation to help minimize gastrointestinal symptoms.
Serious Risks & Contraindications
-
Thyroid C-Cell Tumors
In animal studies, GLP-1 receptor agonists have caused thyroid C-cell tumors. It is unknown whether tirzepatide causes these tumors in humans. Tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
-
Pancreatitis
Cases of acute pancreatitis have been reported. Patients should be monitored for signs and symptoms. Discontinue if pancreatitis is suspected.
-
Gallbladder Events
Cholelithiasis and cholecystitis have been reported. Patients should be informed of symptoms of gallbladder disease.
-
Pregnancy
Tirzepatide should not be used during pregnancy or while breastfeeding. Patients should discontinue at least 2 months before a planned pregnancy.
About Compounded Tirzepatide
Compounded tirzepatide is prepared by a licensed compounding pharmacy and contains the same active ingredient as branded versions. However, compounded medications are not FDA-approved and may differ in inactive ingredients, formulation, and manufacturing processes. Your provider will explain these differences during your consultation.
Frequently Asked Questions
Detailed answers about tirzepatide treatment, safety, and what to expect.
Ready to Learn If Tirzepatide May Be Right for You?
Connect with a licensed provider for a secure, confidential evaluation.
Get StartedCompounded tirzepatide is not FDA-approved. All treatments require evaluation and prescription by a licensed healthcare provider. Individual results may vary. This information is not intended to diagnose, treat, cure, or prevent any disease.